Reumuth Mary

CHIEF FINANCIAL OFFICERKALA BIO, Inc. (KALA) · full profile →Form 4 · filed Jan 5, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$8K
Net Open-Market Flow
-$8K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 4, 2024Grant(A)5K$067K
Jan 4, 2024Sell(S)1K$6.74$8K66K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 4, 2024Grant(A)21K$021K

Transaction Codes

A
Grant / award
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-24-000767) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Ask your agent about KALA insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001415889-24-000767"
Ask your agent
Use Arkolith to summarize insider buying and selling at KALA BIO, Inc.
over the last 90 days and cite the filings.